Table of Contents
ABOUT THIS PROFILE
- PharmaVitae Explorer database
- Chapter structure
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales and growth rate performance, 2002 - 14
- Financial performance, 2002 - 14
- Allergan: PharmaVitae forecasts at a glance
- Strategic insight
- Botox plays a central role in Allergan' s synergistic expansion
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- M&A activity
- Company announcements
- Future product milestones
COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- M&A history
- Acquired by SmithKline Beckman
- Allergan spun-out from SmithKline Beckman
- Acquisition of Oculinum
- Divestment of Allergan Humphrey
- Divestment of contact lens businesses
- Five acquisitions were made in and around 1995
- Allergan Specialty Therapeutics spun-out
- Allergan Specialty Therapeutics re-acquired
- Bardeen Sciences set-up
- Advanced Medical Optics spun-out
- Bardeen Sciences acquired
- Oculex acquired
- Acquistition of Inamed
- Groupe Corneal Laboratoires acquired
- EndoArt acquired
- Acquisition of Esprit Pharma
- Current corporate structure
- Pharmaceuticals
- Allergan Medical
COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
- Product analysis
- Product analysis, 2002 - 08
- Product analysis, 2008 - 14
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2008 - 14
- Core analysis, 2008 - 14
- Expiry analysis, 2008 - 14
- Launch/core/expiry configuration, 2008 - 14
- Molecule type analysis
- Externalization analysis
COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and
company-reported total sales, 2002 - 08
- Operating costs and profit analysis
- Operating costs and profit analysis, 2002 - 08
- Operating cost ratio and profit margin analysis, 2002 - 08
- Operating cost ratio and profit margin analysis, 2008 - 14
- Operating costs and profit analysis, 2008 - 14
KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Central nervous system
- Other (ophthalmology)
- Restasis
- Lumigan franchise
- Alphagan franchise
- Ozurdex
APPENDIX
- R&D pipeline
- Reconciliation with reported figures
- References
- Abbreviations
- Exchange rates
TABLES
- Table: Allergan - PharmaVitae forecasts at a glance
- Table: Allergan key product developments, Q1 - Q2 2009
- Table: Allergan product deals and alliances, Q1 - Q2 2009
- Table: Allergan technology deals and alliances, Q1 - Q2 2009
- Table: Allergan M&A activity, Q1 - Q2 2009
- Table: Allergan company announcements, Q1 - Q2 2009
- Table: Allergan future product milestones, 2009 - 11
- Table: Allergan product portfolio overview ($m), 2002 - 08
- Table: Allergan product portfolio overview ($m), 2008 - 14
- Table: Allergan prescription pharmaceutical sales by therapy area ($m),
2008 - 14
- Table: Allergan prescription pharmaceutical sales by geographic region
($m), 2008 - 14
- Table: Allergan launch portfolio overview ($m), 2008 - 14
- Table: Allergan core portfolio overview ($m), 2008 - 14
- Table: Allergan expiry portfolio overview ($m), 2008 - 14
- Table: Allergan prescription pharmaceutical sales by molecule type ($m),
2008 - 14
- Table: Allergan prescription pharmaceutical sales by source ($m), 2008 - 14
- Table: Total Allergan sales by business unit ($m), 2002 - 08
- Table: Allergan operating revenue/cost analysis ($m), 2002 - 08
- Table: Allergan operating cost ratio analysis (% of total revenues), 2002
- 08
- Table: Allergan operating cost ratio analysis (% of total revenues), 2008
- 14
- Table: Allergan operating revenue/cost analysis ($m), 2008 - 14
- Table: Key products overview
- Table: Botox: overview
- Table: Botox: sales forecast ($m), 2008 - 14
- Table: Restasis: overview
- Table: Restasis: sales forecast ($m), 2008 - 14
- Table: Lumigan franchise: overview
- Table: Lumigan franchise: sales forecast ($m), 2008 - 14
- Table: Alphagan franchise: overview
- Table: Alphagan franchise: sales forecast ($m), 2008 - 14
- Table: Ozurdex: overview
- Table: Ozurdex: sales forecast ($m), 2008 - 14
- Table: Latisse: overview
- Table: Latisse: sales forecast ($m), 2008 - 14
- Table: Allergan' s R&D pipeline (Phase I - registration)
- Table: Total Allergan revenue by business unit and product line ($m), 2002
- 08
- Table: Exchange rates, 2009
FIGURES
- Figure: The PharmaVitae Explorer
- Figure: Allergan prescription pharmaceutical performance, sales ($m) and
growth rate (%), 2002 - 14
- Figure: Allergan' s financial performance ($m), 2002 - 14
- Figure: Allergan prescription pharmaceutical sales ($m), 2002 - 14
- Figure: The central role of Botox in Allergan' s strategic moves
- Figure: Allergan SWOT analysis
- Figure: Allergan' s M&A history
- Figure: Current corporate structure
- Figure: Allergan prescription pharmaceutical performance, sales ($m) and
growth rate (%), 2002 - 14
- Figure: Key product sales ($m), 2002 - 14
- Figure: Allergan key sales growth drivers and resistors ($m), 2002 - 08
- Figure: Allergan key sales growth drivers and resistors ($m), 2008 - 14
- Figure: Allergan prescription pharmaceutical sales by therapy area ($m),
2002 - 14
- Figure: Allergan prescription pharmaceutical sales by geographic region
($m), 2002 - 14
- Figure: Allergan launch/core/expiry configuration ($m), 2008 - 14
- Figure: Allergan prescription pharmaceutical sales by molecule type ($m),
2002 - 14
- Figure: Allergan prescription pharmaceutical sales by source ($m), 2002 -
14
- Figure: Allergan operating revenue/cost analysis ($m), 2002 - 14
- Figure: Mechanisms by which current treatments reduce intraocular pressure
|
Related Report
|
View Cart
